Recent Updates
Recently added Catalysts

EDP1867

Phase 1

Atopic Dermatitis | Small Molecules | Respiratory |Evelo Biosciences, Inc.|Trials Updated: Oct 7, 2022

EDP1867 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Jun 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment52

FDA Designations

No designations recorded

EDP1867 clinical trials

EDP1867 · 1 trial · 3 indications

Phase 1 1
NCT04927195Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild AsthmaAtopic Dermatitis
COMPLETED52 Analytics
PHASE1COMPLETED
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
Atopic DermatitisUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability measured through Adverse Events (AEs)
Day 1 to Day 70

Number of participants with AEs by seriousness and relationship to treatment

Safety and tolerability measured through lab measurements
Day 1 to Day 70

Number of participants with clinically significant change from baseline (Day 0) in laboratory values

Safety and tolerability measured through ECG
Day 1 to Day 70

Number of participants with clinically relevant changes from baseline (Day 0) ECG parameters

Safety and tolerability measured through physical examination
Day 1 to Day 70

Physical examination will include, at a minimum, assessments of the cardiovascular, respiratory, oral cavity, GI and neurological systems. Height and weight will also be measured and recorded. Number of participants with clinically relevant changes from baseline (Day 0) physical examination parameters

Safety and tolerability measured through vital signs
Day 1 to Day 70

Blood pressure, pulse rate, respiratory rate, oxygen saturations and temperature will be assessed. Number of participants with clinically relevant changes in vital signs from baseline (Day 0)

Secondary Endpoints

Change in EASI score
Day 1 to Day 70
Percentage change in EASI score
Day 1 to Day 70
Change in SCORAD score
Day 1 to Day 70
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1EXPERIMENTAL12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 7.5 x 10\^11 cells, capsules, once daily, 14 days total
Cohort 2EXPERIMENTAL12 healthy volunteers; 8 on EDP1867, 4 on placebo. Dose = upto 1.5 x 10\^12 cells, capsules, once daily, 14 days total
Cohort 3EXPERIMENTAL24 subjects with moderate atopic dermatitis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days
Cohort 4EXPERIMENTAL24 subjects with moderate psoriasis; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days
Cohort 5EXPERIMENTAL24 subjects with mild asthma; 16 on EDP1867, 8 on placebo. Dose = 7.5 x 10\^11 cells, capsules, once daily, 56 days

Interventions

NameTypeDescription
EDP1867DRUGEDP1867 is an orally administered, pharmaceutical preparation of a single strain of bacteria
PlaceboDRUGPlacebo oral capsule
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites7

Key Inclusion Criteria: 1. Age ≥ 18 years to 65 years. 2. Participant has a body mass index of ≥ 18 kg/m2 to ≤ 35 kg/m2. 3. Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG monitoring at Screening and...

Countries:United Kingdom
Unlock Eligibility Criteria